Table 4.
Response (percent) to therapy during various phases of the trial
| Percent of patients achieving Level | Pedi 30 | Pedi 50 | Pedi 70 | Pedi 90 | Pedi 100 | Inactive disease |
|---|---|---|---|---|---|---|
| Lead-in open-label (n = 190) | 65 | 50 | 28 | 13 | NA | 13 |
| DB abatacept (n = 60) | 82 | 77* | 53* | 40* | NA | 30* |
| DB placebo (n = 62) | 69 | 52* | 31* | 16* | NA | 11* |
| LTE continuous abatacept (n = 51), day 589 | 90 | 88 | 75 | 57 | 20 | 43* |
| LTE interrupted treatmenta (n = 47), day 589 | 87 | 83 | 75 | 40 | 19 | 22* |
| LTE lead-in phase nonresponders (n = 22), day 589 | 73 | 64 | 46* | 18* | 0* | 3* |
Notes:
a
Patients who received placebo during the double-blind withdrawal phase;
*
Statistically significant differences.
Abbreviations: Pedi, American College of Rheumatology pediatric response rate; DB, double blind; LTE, Open-label long-term extension; NA, not available.